Clinical trial · no report yet · Phase 3
NCT02912559
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
- NCT02912559 ↗
- Active not recruiting
- National Cancer Institute (NCI)
- 4 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Colon Adenocarcinoma; DNA Repair Disorder; Lynch Syndrome; Stage III Colon Cancer AJCC v8
- Interventions
- Atezolizumab; Biospecimen Collection; Computed Tomography; Fluorouracil; Leucovorin Calcium; Magnetic Resonance Imaging; Oxaliplatin; Quality-of-Life Assessment
- Arms
- Arm I (combination chemotherapy, atezolizumab) · Experimental
- Arm II (combination chemotherapy) · Active comparator
- Enrollment
- 712
- Primary outcomes
- Disease Free Survival (DFS)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Oct 16, 2017
- Primary completion
- Feb 4, 2025
- Results posted
- Yes
- Registry record
- NCT02912559 · updated Oct 1, 2026
Publications
linked from the registry- Sinicrope FA, Ou FS, Arnold D, Peters WR, Behrens RJ, Lieu CH, Matin K, Cohen DJ, Potter SL, Nixon AB, Kottschade LA, Kathol E, Frankel WL, Shergill A, Hsu D, Reinacher-Schick A, Mehan P, Gold PJ, Khalil MF, Zemla T, Gatten C, O'Reilly EM, Meyerhardt JA. Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2026 Mar 26;394(12):1155-1166. doi: 10.1056/NEJMoa2507874. PubMed 41880612
- Langenfeld SJ, Raman S, Gribovskaja-Rupp I. Selected Abstracts. Dis Colon Rectum. 2025 Oct 1;68(10):1224-1230. doi: 10.1097/DCR.0000000000003879. Epub 2025 Jul 9. No abstract available. PubMed 40953502